Lyell Immunopharma, Inc. (LYEL) earnings
LYEL earnings moved a median of +5.07% by the close. Quarterly and annual LYEL reports and results, each read against the price at its own news timestamp. Back to the LYEL overview →
21 measured LYEL earnings events.
Where these LYEL earnings landedvs 19 measured LYEL earnings reactions
| Middle 50% of LYEL earnings reactions | -3.02% to +7.14% |
|---|---|
| Median reaction (to close) | +5.07% |
| Measured reactions | 19 |
Point-in-time · zero look-ahead
Half of the 19 LYEL earnings events with a measured close landed between -3.02% and +7.14%; 58% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Lyell Immunopharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | +3.29% | +5.07% | |
| Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 | Press release | +3.29% | +5.07% | |
| Form 10-Q Lyell Immunopharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | -4.57% | -5.51% | |
| Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026 | Press release | -4.57% | -5.51% | |
| Form 10-K Lyell Immunopharma, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | -14.24% | |
| Form 10-Q Lyell Immunopharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.12% | — | |
| Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 | Press release | -0.12% | — | |
| Form 10-Q Lyell Immunopharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +16.70% | |
| Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025 | Press release | +0.00% | +16.70% | |
| Form 10-Q Lyell Immunopharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | +11.16% | -2.86% | |
| Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 | Press release | +11.16% | -2.86% | |
| Form 10-K Lyell Immunopharma, Inc. For: Dec 31 | SEC filing · Form 10-K | -2.21% | -1.25% | |
| Form 10-Q Lyell Immunopharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | -1.19% | -3.17% | |
| Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024 | Press release | -1.19% | -3.17% | |
| Form 10-Q Lyell Immunopharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | +2.50% | +7.14% | |
| Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024 | Press release | +2.50% | +7.14% | |
| Form 10-Q Lyell Immunopharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.43% | +8.55% | |
| Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024 | Press release | +0.43% | +8.55% | |
| Form 10-K Lyell Immunopharma, Inc. For: Dec 31 | SEC filing · Form 10-K | -1.09% | +6.57% | |
| Form 10-Q Lyell Immunopharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.01% | +5.38% | |
| Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023 | Press release | +0.01% | +5.38% |
Keep exploring
More LYEL: analyst actions → · SEC filings → · LYEL overview →